AlphAIalphai — Financial news for AI agents
yahoo.comJUL 233 min read$SOLV

Solventum’s Q2 2026 Earnings: What to Expect

Solventum (SOLV) is set to report Q2 2026 earnings on Aug. 5 after market close. Analysts expect diluted EPS of $1.91, up from $1.69 a year earlier, and full-year EPS of $6.58. The article cites a Moderate Buy consensus and an average $83.67 price target, while noting concerns over weak growth and deteriorating free cash flow margins.

Original reporting
yahoo.com
Published Jul 23, 2026, 7:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 23, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Solventum’s Q2 2026 Earnings: What to Expect — source image
Source · yahoo.com
Decision brief

The 30-second read

$SOLVNeutralMed
01

Why it matters

The main tradable element is the earnings timing (Aug. 5 after the close) and the consensus EPS benchmarks ($1.91 Q2, $6.58 full-year), against a backdrop of flat sales and margin deterioration concerns.

02

Market read

Traders can use the consensus EPS targets and the stated growth/margin concerns to gauge what would constitute a beat or miss and what guidance language could move the stock.

03

What to watch

The article emphasizes deteriorating free-cash-flow margins and flat sales expectations, but does not specify segment performance or cost actions that could swing the earnings narrative.

Relevance 4/10Novelty 4/10Timing: Ahead of Aug. 5 after-hours Q2 2026 earnings release.

Background

Solventum (SOLV) is a healthcare technology company that spun off from 3M, and the article frames investor concerns around weak growth and profitability.

Company-level read

Ticker impact

$SOLVNeutralMedium confidence
Context

Article previews Solventum’s Q2 2026 earnings on Aug. 5 after the close, citing expected EPS of $1.91 and full-year EPS $6.58.

Expected impact

Near-term volatility likely around Aug. 5 results versus the $1.91 EPS expectation, with upside/downside driven by any surprise on growth and cash-flow margins.

Evidence & confidence

The text provides consensus figures and highlights specific investor worries (flat sales, weak organic growth, margin deterioration), which typically shape positioning into the print.

Market effects

Sector

Could influence sentiment toward healthcare med-tech/spin-off stories if results confirm or refute flat-sales and margin-compression concerns.

Regional

Limited, primarily US healthcare large-cap sentiment.

Global

Low; the catalyst is company-specific earnings guidance versus consensus.

Counterpoint

What could challenge this read

If Solventum has a history of beating consensus (noted as four straight quarters), the market may already be positioned for a beat, making guidance and cash-flow commentary more decisive than EPS alone.

Key entities

  • company
    Solventum Corporation

    Subject of the earnings preview, with consensus EPS expectations and noted profitability/cash-flow concerns.

  • index
    S&P 500 Index

    Used only as a performance comparison benchmark in the article.

  • ETF
    State Street Health Care Select Sector SPDR Fund (XLV)

    Used only as a performance comparison benchmark in the article.

Read at source← All news

Related articles

AUG 6
$SOLVMedAI 8/10

Solventum to hive off healthcare software business, raises profit forecast

Solventum said it will separate its health information systems software business, leaving MedSurg and Dental Solutions, as part of its turnaround. The unit accounted for 16.3% of 2025 sales. Solventum raised 2026 organic sales growth to 2.5% to 3% and adjusted profit per share to $7.10 to $7.20. Q2 adjusted EPS was $2.55 on revenue of $2.21B, beating LSEG estimates.

wixx.com4 min
AUG 5
$SOLVMedAI 8/10

Solventum (NYSE:SOLV) Posts Better

Solventum (NYSE:SOLV) reported Q2 CY2026 results with revenue up 2.2% year on year to $2.21 billion, beating market expectations. Non-GAAP EPS was $2.55, 33.8% above analysts’ consensus. The article also cites trailing 12-month sales of $8.31 billion, flat over two years, and Q2 free cash flow of $144 million. Shares rose 3.7% to $90.75.

financialcontent.com5 min
AUG 5
$SOLVHighAI 9/10

Solventum Reports Second Quarter 2026 Financial Results

Solventum (NYSE: SOLV) reported Q2 2026 sales of $2.2 billion, up 2.2% reported and 9.5% organic. GAAP diluted EPS was $0.53, adjusted $2.55. Operating cash flow was $227 million and free cash flow $144 million. The company said it intends to separate its Health Information Systems segment and raised full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow.

prnewswire.com4 min
AUG 5
$SOLVHigh

Solventum Corp (SOLV): Results of Operations and Financial Condition

Solventum Corp (SOLV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026-8kerexx991.htm EX-99.1 Document Exhibit 99.1 Solventum Reports Second Quarter 2026 Financial Results • R eported sales increased 2.2%; organic sales increased 9.5% • Announces intent to separate its Health Information Systems business segment • Increases full-yea

SEC EDGAR 8-K6 min
MAY 26
$SOLVMedAI 8/10

Weekly Research Analysts’ Ratings Changes for Solventum (SOLV)

Solventum (NYSE: SOLV) saw multiple analyst rating and target changes. Wedbush initiated coverage with an “outperform” rating and $94 target (5/15/26). UBS downgraded to “neutral” with $50 target (5/14/26) and previously cut its target to $78 (5/6/26). Other firms adjusted targets and ratings on 5/6/26, including Stifel ($90, buy), KeyCorp ($93, overweight), Wells Fargo ($70, equal weight), and BTIG ($89, buy). Director Amy Mcbride Wendell bought 1,475 shares at $68.03 (3/10/26).

tickerreport.com1 min
AUG 8
$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

yahoo.com6 min